INmune Bio stock holds steady as Raymond James reiterates Market Perform

Published 04/08/2025, 18:10
INmune Bio stock holds steady as Raymond James reiterates Market Perform

Investing.com - Raymond (NSE:RYMD) James has reiterated its Market Perform rating on INmune Bio Inc. (NASDAQ:INMB), currently trading near $2.81, following the company’s announcement of positive clinical trial results. According to InvestingPro data, three analysts have recently revised their earnings upward for the upcoming period, with price targets ranging from $0.60 to $8.00.

INmune Bio successfully completed its Phase 1/2 CaRe PC trial evaluating INKmune in patients with metastatic castration-resistant prostate cancer (mCRPC), meeting both primary and secondary endpoints with a solid safety profile and promising signs of immunologic and tumor responses.

The trial utilized a Bayesian dose-escalation design across three ascending dose cohorts, identifying patients with low baseline NK cell activation as the optimal target population for future development. With enrollment now closed, INmune Bio is preparing to initiate a randomized Phase 2b trial in a less advanced mCRPC population.

Raymond James noted that while the INKmune program shows progress, investor focus remains primarily on the company’s XPro program in Alzheimer’s, which produced disappointing Phase 2 data in late June.

The research firm highlighted INmune Bio’s limited financial resources, with approximately $38 million in cash following a June 27 registered direct offering, providing about 12 months of runway, and expects the company to seek partners to advance its various programs including INKmune.

In other recent news, INmune Bio Inc. announced that its Phase I/II trial of INKmune™ in metastatic castration-resistant prostate cancer met both primary and secondary endpoints. The trial demonstrated an excellent safety profile across all dose levels, with significant improvements in biomarkers for patients with low natural killer cell activation. Meanwhile, INmune Bio plans to present additional analyses from its Phase 2 MINDFuL trial of XPro for Alzheimer’s disease at an upcoming conference. However, the Alzheimer’s trial results were mixed, leading Lucid (NASDAQ:LCID) Capital Markets to downgrade the company’s stock from Buy to Neutral. Lucid Capital also reduced its price target from $25.00 to $2.00. The trial did not meet its primary endpoint in the full cohort, although there was potential benefit observed in a specific subpopulation. Following these results, Raymond James also downgraded INmune Bio from Outperform to Market Perform. The Phase 2 study for XPro failed to achieve its primary endpoint concerning cognitive function in early Alzheimer’s patients.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.